vs
Side-by-side financial comparison of HANCOCK WHITNEY CORP (HWC) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $295.0M, roughly 1.0× HANCOCK WHITNEY CORP). HANCOCK WHITNEY CORP runs the higher net margin — 16.1% vs 12.8%, a 3.2% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-6.4% vs -19.7%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -9.4%).
Hancock Whitney Corp. is an American bank holding company headquartered in Gulfport, Mississippi. It operates 237 branches in Mississippi, Alabama, Florida, Louisiana, and Texas. The bank is the official bank of the New Orleans Saints and issues the official debit card. The bank is also the official bank of LSU Athletics and the Louisiana Ragin' Cajuns, being the exclusive provider of credit cards for the LSU Tigers, as well as debit cards for both athletic brands.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
HWC vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.0M | $295.9M |
| Net Profit | $47.4M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 16.1% | 12.8% |
| Revenue YoY | -19.7% | -6.4% |
| Net Profit YoY | -60.3% | 68.3% |
| EPS (diluted) | $0.57 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $295.0M | — | ||
| Q4 25 | $389.3M | $295.9M | ||
| Q3 25 | $385.7M | — | ||
| Q2 25 | $375.5M | $317.0M | ||
| Q1 25 | $364.7M | $316.2M | ||
| Q4 24 | $364.8M | $297.0M | ||
| Q3 24 | $367.7M | $289.5M | ||
| Q2 24 | $359.6M | $306.1M |
| Q1 26 | $47.4M | — | ||
| Q4 25 | — | $38.0M | ||
| Q3 25 | $127.5M | — | ||
| Q2 25 | — | $-17.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $115.6M | $33.6M | ||
| Q2 24 | — | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 40.7% | 18.4% | ||
| Q3 25 | 41.6% | — | ||
| Q2 25 | 38.5% | -7.5% | ||
| Q1 25 | 40.9% | 12.2% | ||
| Q4 24 | 41.3% | 16.0% | ||
| Q3 24 | 39.5% | 13.8% | ||
| Q2 24 | 40.3% | 15.0% |
| Q1 26 | 16.1% | — | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | — | -5.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 31.4% | 11.6% | ||
| Q2 24 | — | 13.3% |
| Q1 26 | $0.57 | — | ||
| Q4 25 | $1.48 | $0.24 | ||
| Q3 25 | $1.49 | — | ||
| Q2 25 | $1.32 | $-0.11 | ||
| Q1 25 | $1.38 | $0.14 | ||
| Q4 24 | $1.40 | $0.22 | ||
| Q3 24 | $1.33 | $0.21 | ||
| Q2 24 | $1.31 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $223.7M | $172.9M |
| Total DebtLower is stronger | $1.6B | $260.0M |
| Stockholders' EquityBook value | — | $2.0B |
| Total Assets | $35.5B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $223.7M | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $199.4M | $260.0M | ||
| Q3 25 | $210.7M | — | ||
| Q2 25 | $210.6M | $346.0M | ||
| Q1 25 | $210.6M | $330.0M | ||
| Q4 24 | $210.5M | $300.0M | ||
| Q3 24 | $236.4M | $300.0M | ||
| Q2 24 | $236.4M | $319.0M |
| Q1 26 | — | — | ||
| Q4 25 | $4.5B | $2.0B | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.4B | $1.9B | ||
| Q1 25 | $4.3B | $2.0B | ||
| Q4 24 | $4.1B | $2.1B | ||
| Q3 24 | $4.2B | $2.1B | ||
| Q2 24 | $3.9B | $2.1B |
| Q1 26 | $35.5B | — | ||
| Q4 25 | $35.5B | $2.5B | ||
| Q3 25 | $35.8B | — | ||
| Q2 25 | $35.2B | $2.6B | ||
| Q1 25 | $34.8B | $2.6B | ||
| Q4 24 | $35.1B | $2.7B | ||
| Q3 24 | $35.2B | $2.7B | ||
| Q2 24 | $35.4B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.04× | 0.13× | ||
| Q3 25 | 0.05× | — | ||
| Q2 25 | 0.05× | 0.18× | ||
| Q1 25 | 0.05× | 0.16× | ||
| Q4 24 | 0.05× | 0.14× | ||
| Q3 24 | 0.06× | 0.14× | ||
| Q2 24 | 0.06× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HWC
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
